Cytokeratin fragments in the serum: Their utility for the management of oral cancer

Oral Oncology

Volumn 44, Issue 8, 2008, Pages 722-732

  Sawant, Sharada S ^a   Zingde, Surekha M ^a   Vaidya, Milind M ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cyfra 21 1; Cytokeratins; Diagnosis; Oral cancer; Prognosis; Serum tumour markers; TPA; TPS

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; CYTOKERATIN ANTIBODY; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MORBIDITY; MOUTH CANCER; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TOBACCO;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INDIA; KERATINS; LYMPHATIC METASTASIS; MALE; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TOBACCO, SMOKELESS; TUMOR MARKERS, BIOLOGICAL;

EID: 47249139572     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.10.008     Document Type: Review

References (160)

1. Federle D.J., Adelson R., Nilessen L.C., and Harrison R. Oral cavity and pharyngeal cancer among Department of veterans affairs hospital discharges. J Public Health Dent 55 (1995) 143-147
2. Nandkumar A. Consolidated report of the population based cancer registries 1990-1996; Incidence and distribution of cancer. National Cancer Registry Programme by ICMR, New Delhi, 1996.
3. Pindborg J.J., Reichart P.A., Smith C.J., and Van der Wall I. Histopathological typing of cancer and precancer of the oral mucosa. 2nd ed. (1997), Springer, Berlin
4. Brunin F., Mosseri V., Jaulerry C., Pioint D., Cosset J.M., and Rodriguez J. Cancer of the base of the tongue: past and future. Head Neck 21 8 (1999) 751-759
5. Mork J. Forty years of monitoring head and neck cancer in Norway-no good news. Anticancer Res 18 (1998) 3705-3708
6. Matsubara Y., Yasuda Y., Hanawa T., Miyamoto Y., Ninomiya K., Hatakenaka R., et al. SCC-antigen in patients with lung cancer. Nippon Gan Chiryo Gakkai Shi 21 5 (1986) 1036-1048
7. Doweck I., Barak M., Greenberg E., Uri N., Kellner J., Lurie M., et al. Cyfra 21-1 A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121 2 (1995) 177-181
8. Silverman N.A., Alexander Jr. J.C., and Chretien P.B. CEA levels in head and neck cancer. Cancer 37 5 (1976) 2204-2211
9. Katopodis N., Hirshaut Y., Geller N.L., and Stock C.C. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 42 12 (1982) 5270-5275
10. Yoshimura Y., Oka M., and Harada T. Squamous cell carcinoma-antigen for detection of squamous cell and mucoepidermoid carcinoma after primary treatment: a preliminary report. J Oral Maxillofac Surg 48 12 (1990) 1288-1292 discussion 1292-1283
11. Walther E.K., Dahlmann N., and Gorgulla H.T. Tumor markers in patients with head-neck carcinomas. Laryngorhinootologie 69 5 (1990) 271-274
12. Calsen B., Pere P., Senekowitsch R., and Menz E. SCC as a tumour marker in the initial diagnosis of carcinoma of the head and neck region. Laryngorhinootologie 65 (1990) 275-280
13. Ropka M.E., Goodwin W.J., Levine P.A., Sasaki C.T., Kirchner J.C., and Cantrell R.W. Effective head and neck tumor markers. The continuing quest. Arch Otolaryngol Head Neck Surg 117 9 (1991) 1011-1014
14. Wollenberg B., Jan N., Sautier W., Hofmann K., Schmitt U.M., and Stieber P. Serum levels of intercellular adhesion molecule-1 in squamous cell carcinoma of the head and neck. Tumour Biol 18 2 (1997) 88-94
15. Ogawa T., Tsurusako Y., Kimura N., Nishioka S., Akagi H., Nishizaki K., et al. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol Suppl 540 (1999) 72-76
16. Ayude D., Gacio G., Paez de la Cadena M., Pallas E., Martinez-Zorzano V.S., de Carlos A., et al. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep 10 5 (2003) 1345-1350
17. Schweizer J., Bowden P.E., Coulombe P.A., Langbein L., Lane E.B., Magin T.M., et al. New consensus nomenclature for mammalian keratins. J Cell Biol 174 2 (2006) 169-174
18. Bodenmuller H., Ofenloch-Hahnle B., Lane E.B., Dessauer A., Bottger V., and Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers 9 2 (1994) 75-81
19. Einarsson R., and Rydlander L. Tissue polypeptide specific antigen (TPS) detects a specific epitope structure on human cytokeratin. Anticancer Res 17 4B (1997) 3121-3124
20. Barak V., Goike H., Panaretakis K.W., and Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 37 7 (2004) 529-540
21. Molina R., Torres M.D., Moragas M., Filella X., Jo J., Gimenez N., et al. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 15 2 (1995) 479-484
22. Bongers V., Braakhuis B.J., and Snow G.B. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 20 5 (1995) 479-482
23. Moll R., Franke W.W., Schiller D.L., Geiger B., and Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31 1 (1982) 11-24
24. Lazarides E. Intermediate filaments as mechanical integrators of cellular space. Nature 283 5744 (1980) 249-256
25. Steinert P.M., and Roop D.R. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 57 (1988) 593-625
26. Coulombe P.A. The cellular and molecular biology of keratins: beginning a new era. Curr Opin Cell Biol 5 1 (1993) 17-29
27. Fuchs E., and Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63 (1994) 345-382
28. Coulombe P.A., and Omary M.B. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 14 1 (2002) 110-122
29. Franke W.W., Schmid E., Schiller D.L., Winter S., Jarasch E.D., Moll R., et al. Differentiation-related patterns of expression of proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb Symp Quant Biol 46 Pt 1 (1982) 431-453
30. Clausen H., Vedtofte P., Moe D., Dabelsteen E., Sun T.T., and Dale B. Differentiation-dependent expression of keratins in human oral epithelia. J Invest Dermatol 86 3 (1986) 249-254
31. Moll R., Schiller D.L., and Franke W.W. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 111 2 (1990) 567-580
32. Rogers G.E., and Powell B.C. Organization and expression of hair follicle genes. J Invest Dermatol 101 Suppl. 1 (1993) 50S-55S
33. Quinlan R.A., Schiller D.L., Hatzfeld M., Achtstatter T., Moll R., Jorcano J.L., et al. Patterns of expression and organization of cytokeratin intermediate filaments. Ann N Y Acad Sci 455 (1985) 282-306
34. Nagle R.B., Moll R., Weidauer H., Nemetschek H., and Franke W.W. Different patterns of cytokeratin expression in the normal epithelia of the upper respiratory tract. Differentiation 30 2 (1985) 130-140
35. Kirfel J., Magin T.M., and Reichelt J. Keratins: a structural scaffold with emerging functions. Cell Mol Life Sci 60 1 (2003) 56-71
36. Chou C.F., Smith A.J., and Omary M.B. Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J Biol Chem 267 6 (1992) 3901-3906
37. Omary M.B., Ku N.O., Liao J., and Price D. Keratin modifications and solubility properties in epithelial cells and in vitro. Subcell Biochem 31 (1998) 105-140
38. Ku N.O., and Omary M.B. Expression, glycosylation, and phosphorylation of human keratins 8 and 18 in insect cells. Exp Cell Res 211 1 (1994) 24-35
39. Ku N.O., and Omary M.B. Identification of the major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization. J Cell Biol 127 1 (1994) 161-171
40. Ku N.O., and Omary M.B. Identification and mutational analysis of the glycosylation sites of human keratin 18. J Biol Chem 270 20 (1995) 11820-11827
41. Moll R., Krepler R., and Franke W.W. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 23 3 (1983) 256-269
42. Moll R. Diversity of cytokeratins in carcinomas. Acta Histochem Suppl 34 (1987) 37-44
43. Osborn M., van Lessen G., Weber K., Kloppel G., and Altmannsberger M. Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest 55 4 (1986) 497-504
44. Osborn M., and Weber K. Intermediate filaments: cell-type-specific markers in differentiation and pathology. Cell 31 2 Pt. 1 (1982) 303-306
45. Blobel G.A., Moll R., Franke W.W., Kayser K.W., and Gould V.E. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 121 2 (1985) 235-247
46. Morgan P.R., Shirlaw P.J., Johnson N.W., Leigh I.M., and Lane E.B. Potential applications of anti-keratin antibodies in oral diagnosis. J Oral Pathol 16 4 (1987) 212-222
47. Lindberg K., and Rheinwald J.G. Suprabasal 40 kDa keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Am J Pathol 134 1 (1989) 89-98
48. Vigneshwaran N., Peters K.-P., Hornstein O.P., and Haneke E. Comparison of cytokeratin, filaggrin and involucrin profiles in oral leukoplakias and squamous carcinomas. J Oral Pathol Med 18 (1989) 377-390
49. Bosch F.X., Ouhayoun J.P., Bader B.L., Collin C., Grund C., Lee I., et al. Extensive changes in cytokeratin expression patterns in pathologically affected human gingiva. Virchows Arch B Cell Pathol Incl Mol Pathol 58 1 (1989) 59-77
50. Heyden A., Huitfeldt H.S., Koppang H.S., Thrane P.S., Bryne M., and Brandtzaeg P. Cytokeratins as epithelial differentiation markers in premalignant and malignant oral lesions. J Oral Pathol Med 21 1 (1992) 7-11
51. Nagle R.B. A review of intermediate filament biology and their use in pathologic diagnosis. Mol Biol Rep 19 1 (1994) 3-21
52. Vaidya M.M., Borges A.M., Pradhan S.A., Rajpal R.M., and Bhisey A.N. Altered keratin expression in buccal mucosal squamous cell carcinoma. J Oral Pathol Med 18 5 (1989) 282-286
53. Vaidya M.M., Borges A.M., Pradhan S.A., and Bhisey A.N. Cytokeratin expression in squamous cell carcinomas of the tongue and alveolar mucosa. Eur J Cancer B Oral Oncol 32B 5 (1996) 333-336
54. Sawant S.S., Naresh K.N., D'Cruz A., Ogale S.B., and Vaidya M.M. Demonstration of cytokeratin-5 non-expression in tobacco related oral carcinogenesis - use of reverse transcriptase polymerase chain reaction as a sensitive assay. Oral Oncol 39 8 (2003) 789-795
55. Lane E.B., and Alexander C.M. Use of keratin antibodies in tumor diagnosis. Semin Cancer Bio 1 3 (1990) 65-79
56. Chu P.G., and Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology 40 5 (2002) 403-439
57. Ranganathan K., Kavitha R., Sawant S.S., and Vaidya M.M. Cytokeratin expression in oral submucous fibrosis - an immunohistochemical study. J Oral Pathol Med 35 1 (2006) 25-32
58. Kannan S., Balaram P., Chandran G.J., Pillai M.R., Mathew B., Nalinakumari K.R., et al. Alterations in expression of terminal differentiation markers of keratinocytes during oral carcinogenesis. Pathobiology 62 3 (1994) 127-133
59. Raul U., Sawant S., Dange P., Kalraiya R., Ingle A., and Vaidya M. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. Int J Cancer 111 5 (2004) 662-668
60. Casanova M.L., Bravo A., Martinez-Palacio J., Fernandez-Acenero M.J., Villanueva C., Larcher F., et al. Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice. FASEB J 18 13 (2004) 1556-1558
61. Gires O., Mack B., Rauch J., and Matthias C. CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. Biochem Biophys Res Commun 343 1 (2006) 252-259
62. Maass J.D., Niemann A.M., Lippert B.M., Gottschlich S., Folz B.J., and Werner J.A. CYFRA 8/18 in head and neck cancer. Anticancer Res 19 4A (1999) 2699-2701
63. Markey A.C., Lane E.B., Churchill L.J., MacDonald D.M., and Leigh I.M. Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. J Invest Dermatol 97 5 (1991) 763-770
64. Larcher F., Bauluz C., Diaz-Guerra M., Quintanilla M., Conti C.J., Ballestin C., et al. Aberrant expression of the simple epithelial type II keratin 8 by mouse skin carcinomas but not papillomas. Mol Carcinog 6 2 (1992) 112-121
65. Schaafsma H.E., Van Der Velden L.A., Manni J.J., Peters H., Link M., Rutter D.J., et al. Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma. J Pathol 170 1 (1993) 77-86
66. Thomas F., Richard W., Jens P., Burkhard B., Philippe M., Dieter W., et al. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer 6 (2006) 10
67. Johansson A., Sandstrom P., Ullen A., Behravan G., Erlandsson A., Levi M., et al. Epitope specificity of the monoclonal anticytokeratin antibody TS1. Cancer Res 59 1 (1999) 48-51
68. Stigbrand T. The versatility of cytokeratins as tumor markers. Tumour Biol 22 1 (2001) 1-3
69. Wollenberg B., Jan V., Schmit U.M., Hofmann K., Stieber P., and Fateh-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 16 5B (1996) 3117-3124
70. Buccheri G., and Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. Chest 93 3 (1988) 565-570
71. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., and Michel F.B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53 1 (1993) 61-66
72. Nisman B., Barak V., Heching N., Kramer M., Reinus C., and Lafair J. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect Prev 22 5 (1998) 416-421
73. Doweck I., Barak M., Uri N., and Greenberg E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83 12 (2000) 1696-1701
74. Maass J.D., Hoffmann-Fazel A., Goeroegh T., Hoffmann M., Meyer J.E., Gottschlich S., et al. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res 20 3B (2000) 2241-2243
75. Hoffmann-Fazel A., Hoffmann M., Gottschlich S., Maass J.D., Rudert H., and Maune S. Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma. Anticancer Res 23 2A (2003) 917-920
76. Nagler R.M., Barak M., Peled M., Ben-Aryeh H., Filatov M., and Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 85 5 (1999) 1018-1025
77. Banal A., Hacene K., Berthelot-Ruff E., Mahe E., Fontana X., and Pichon M.F. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol 22 1 (2001) 27-35
78. Rydlander L., Ziegler E., Bergman T., Schoberl E., Steiner G., Bergman A.C., et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 241 2 (1996) 309-314
79. Stigbrand T., Andres C., Bellanger L., Bishr Omary M., Bodenmuller H., Bonfrer H., et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol 19 2 (1998) 132-152
80. Ueno T., Toi M., and Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59 Suppl. 2 (2005) S359-S362
81. Brabon A.C., Williams J.F., and Cardiff R.D. A monoclonal antibody to a human breast tumor protein released in response to estrogen. Cancer Res 44 6 (1984) 2704-2710
82. Ku N.O., Liao J., and Omary M.B. Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272 52 (1997) 33197-33203
83. Yen T.C., Lin W.Y., Kao C.H., Cheng K.Y., and Wang S.J. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 23 1 (1998) 82-86
84. Ebert W., Bodenmuller H., and Holzel W. CYFRA 21-1 - clinical applications and analytical requirements. Scand J Clin Lab Invest Suppl 221 (1995) 72-80
85. Stieber P., Dienemann H., Hasholzner U., Muller C., Poley S., Hofmann K., et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 31 10 (1993) 689-694
86. Rastel D., Ramaioli A., Cornillie F., and Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer A 30 5 (1994) 601-606
87. Lagarde A., Forgach T., Nagy D., Nagy K., Vasas S., and Janoki G.A. Diagnostic sensitivity of three tumour markers in non-small cell lung cancer: a pilot study. Nucl Med Rev Cent East Eur 3 2 (2000) 139-142
88. Sun S.S., Hsieh J.F., Tsai S.C., Ho Y.J., Lee J.K., and Kao C.H. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Am J Clin Oncol 23 3 (2000) 241-243
89. Miedouge M., Devys A., Simon M., Rouzaud P., Salama G., Reyre J., et al. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients. Tumour Biol 22 1 (2001) 19-26
90. Seregni E., Coli A., and Mazzucca N. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31 Suppl. 1 (2004) S15-S22
91. Carpelan-Holmstrom M., Haglund C., Lundin J., Alfthan H., Stenman U.H., and Roberts P.J. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 74 6 (1996) 925-929
92. Weber K., Osborn M., Moll R., Wiklund B., and Luning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 3 11 (1984) 2707-2714
93. Prados C., Alvarez-Sala R., Gomez de Terrero J., Callol L., Garcia Rio F., Gomez Carrera L., et al. An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients. Jpn J Clin Oncol 30 5 (2000) 215-220
94. Luning B., Wiklund B., Redelius P., and Bjorklund B. Biochemical properties of tissue polypeptide antigen. Biochim Biophys Acta 624 1 (1980) 90-101
95. Sliwowska I., Kopczyński Z., and Grodecka-Gazdecka S. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Postepy Hig Med Dosw 60 (2006) 295-299
96. Bjorklund B., and Bjorklund V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 10 3 (1957) 153-184
97. Kirsch J., Oehr P., and Winkler C. Localization of tissue poly- peptide antigen in interphase HeLa cells by immunofluorescence microscopy. Tumor Diagn Ther 4 (1983) 222-224
98. Bonfrer J.M., Groeneveld E.M., Korse C.M., van Dalen A., Oomen L.C., and Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumour Biol 15 4 (1994) 210-222
99. Broers J.L., Ramaekers F.C., Rot M.K., Oostendorp T., Huysmans A., van Muijen G.N., et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 48 11 (1988) 3221-3229
100. Rapellino M., Niklinski J., Furman M., Baldi S., Chyczewski L., and Ruffini E. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma. Eur Respir J 8 3 (1995) 407-410
101. Niklinski J., Burzykowski T., Niklinska W., Laudanski J., Chyczewski L., Rapellino M., et al. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 12 6 (1998) 1424-1428
102. Nisman B., Barak V., Shapiro A., Golijanin D., Peretz T., and Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94 11 (2002) 2914-2922
103. Deng Y.F., Chen P., Lin Y.Z., Le J.Z., Wu X.L., Yu M.Q., et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117 3 (2003) 190-194
104. Hagg M., Biven K., Ueno T., Rydlander L., Bjorklund P., and Wiman K.G. A novel high-through-put apoptosis-specific cytokeratin 18 neoepitope M30 in between alteration in growth kinetics by neoadjuvant assay for screening of pro-apoptotic drugs. Invest New Drugs 20 (2002) 253-259
105. Cummings J., Ranson M., LaCasse E., Ganganagari J., St-Jean M., and Jayson M. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95 (2006) 42-48
106. Leers M.P., Kölgen W., Björklund V., Bergman T., Tribbick G., and Persson P. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187 (1999) 567-572
107. Carr N. M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124 (2000) 1768-1772
108. Walker J.A., and Quirke P. Viewing apoptosis through a TUNEL?. J Pathol 195 (2001) 275-276
109. Koornstra J.J., Rijcken F.E.M., de Jong S., Hollema H., de Vries E.G.E., and Kleibeuker J.H. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 44 (2004) 9-17
110. Stieber P, Hatz R, Holdenrieder S, Molina R, Nap M, von Pawel. J. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer. NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Lung Cancer (Section 3P) http://www.nacb.org/lmpg/tumor/chp3p_lung.pdf.
111. Vollmer R.T., Govindan R., Graziano S.L., Gamble G., Garst J., Kelley M.J., et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 9 5 (2003) 1728-1733
112. Holdenrieder S., Stieber P., von Pawel J., Raith H., Nagel D., Feldmann K., et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10 18 Pt. 1 (2004) 5981-5987
113. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90 11 (2004) 2097-2105
114. Rapellino M., Piantino P., Pecchio F., Ruffini E., Cavallo A., Scappaticci E., et al. Disappearance curves of tumor markers after radical surgery. Int J Biol Markers 9 1 (1994) 33-37
115. Ebert W., Muley T., and Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?. Anticancer Res 16 4B (1996) 2161-2168
116. Devine P.L., Yarker J., and Fong K. Serum markers CASA, CEA, CYFRA 21-1, MSA, NSE, TPA and TPS in lung cancer. Int J Oncol 4 (1994) 1129-1135
117. Pujol J.L., Grenier J., Parrat E., Lehmann M., Lafontaine T., Quantin X., et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154 3 Pt 1 (1996) 725-733
118. van Dalen A., Heering K.J., and Barak V. Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumour marker changes. Breast 5 (1996) 82-88
119. van Dalen A., Barak V., and Cremaschi A. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. A multicenter study. Int J Biol Markers 13 (1998) 10-15
120. Nakata B., Ogawa Y., Ishikawa T., Ikeda K., Kato Y., Nishino H., et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 95 3 (2002) 670-671
121. Giai M., Roagna R., Ponzone R., Biglia N., Sgro L., Perona M., et al. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res 16 2 (1996) 875-881
122. Bjorklund B., and Einarsson R. TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer. Tumordiagn Ther 17 (1996) 67-73
123. Barak V., Nisman B., Roisman I., Hubert A., Burde B., and Peretz T. TPS in evaluation of response to Taxol and interferon therapy in breast cancer patients. J Tumor Marker Oncol 9 (1994) 89
124. Giai M., Roagna R., and Ponzone R. TPS and CA15-3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res 15 (1995) 2711-2716
125. Barak V., Nisman B., Roisman I., Hubert A., and Peretz T. Clinical utility of TPS in breast cancer. Tumor Biol (1998) 59
126. Barak V., Nisman B., Hubert A., and Peretz T. TPS-prognosticator in breast cancer. Anticancer Res 18 (1998) 4982
127. Lindman H., Jansson T., Arnberg H., Bergh J., and Einarsson R. Serum markers TPS, TPA and CA 15-3 as monitors of chemotherapy in patients with metastatic breast cancer. J Tumor Marker Oncol 15 (2000) 177-186
128. Findeisen R., Albrecht S., Richter B., Deutschmann K., and Distler W. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer. Clin Chem Lab Med 36 11 (1998) 841-846
129. Soletormos G., Petersen P.H., and Dombernowsky P. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Clin Chem Lab Med 38 5 (2000) 453-463
130. Nekulova M., Simickova M., Pecen L., Eben K., Vermousek I., Stratil P., et al. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction. Neoplasma 41 2 (1994) 113-118
131. Sliwowska I., Kopczynski Z., and Grodecka-Gazdecka S. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Postepy Hig Med Dosw (Online) 60 (2006) 295-299
132. Miyashita T., Nishimura G., Michiwa Y., Sato T., Tsugawa K., Fushida S., et al. [Clinical usefulness of serum CYFRA21-1 in colorectal cancer]. Gan To Kagaku Ryoho 23 12 (1996) 1693-1696
133. Sakahara H., Kousaka T., Hattori N., Hosono M., Kobayashi H., Shirato M., et al. [Evaluation of a cytokeratin 19 assay kit "BALL ELSA CYFRA21-1]. Kaku Igaku 30 12 (1993) 1475-1479
134. Nicolini A., Caciagli M., Zampieri F., Ciampalini G., Carpi A., Spisni R., et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Cancer Detect Prev 19 2 (1995) 183-195
135. Nakata B., Chung Y.S., Kato Y., Ogawa M., Ogawa Y., Inui A., et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73 12 (1996) 1529-1532
136. Berglund A., Molin D., Larsson A., Einarsson R., and Glimelius B. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13 9 (2002) 1430-1437
137. Yachou M., Khemissa-Akouz F., Kramar A., Senesse P., and Grenier J. A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma. Bull Cancer 88 10 (2001) 1023-1027
138. Brockmann J.G., St Nottberg H., Glodny B., Sprakel B., and Senninger N. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Anticancer Res 20 6D (2000) 4899-4904
139. Kawaguchi H., Ohno S., Miyazaki M., Hashimoto K., Egashira A., Saeki H., et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89 7 (2000) 1413-1417
140. Quillien V., Raoul J.L., Laurent J.F., Meunier B., and Le Prise E. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 5 6 (1998) 1561-1565
141. Nakamura T., Ide H., Eguchi R., Hayashi K., Takasaki K., and Watanabe S. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 11 1 (1998) 35-39
142. van Dalen A., Favier J., Baumgartner L., Hasholzner U., de Bruijn H., Dobbler D., et al. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients. Anticancer Res 19 4A (1999) 2523-2526
143. van Dalen A., Favier J., Burges A., Hasholzner U., de Bruijn H.W., Dobler-Girdziunaite D., et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 79 3 (2000) 444-450
144. Gadducci A., Ferdeghini M., Cosio S., Fanucchi A., Cristofani R., and Genazzani A.R. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 11 4 (2001) 277-282
145. Callet N., Cohen-Solal Le Nir C.C., Berthelot E., and Pichon M.F. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Eur J Gynaecol Oncol 19 1 (1998) 50-56
146. Maulard C., Toubert M.E., Chretien Y., Delanian S., Dufour B., and Housset M. Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study. Cancer 73 2 (1994) 394-398
147. Maulard-Durdux C., Toubert M.E., Hennequin C., and Housset M. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J Clin Oncol 15 12 (1997) 3446-3450
148. Schmidt A., Bub P., Ruther U., and Eisenberger F. Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. Eur Urol 21 Suppl. 1 (1992) 10-12
149. van Poppel H., Billen J., Goethuys H., Elgamal A.A., Gerits M., Mortelmans L., et al. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer. Anticancer Res 16 4B (1996) 2205-2207
150. Molina R., Torres M.D., Moragas M., Perez-Villa J., Filella X., Jo J., et al. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol 17 2 (1996) 81-89
151. Sanislo L., and Kausitz J. Predictive value of cytokeratin 18 fragments in patients with locally advanced head and neck tumours. Tumor Biol 24 (2003) 80
152. Niemann A.M., Paulsen J.J., Lippert B.M., Henze E., Gorogh T., and Gottschlich S. Cyfra 21-1 in patients with head and neck cancer. In: Warner J.A., Lippert B.M., and Rudert H.H. (Eds). Head and neck cancer: advances in basic research (1996), Elsevier, Amsterdam 529-537
153. Deng Y.F., Chen P., Lin Y.Z., Le J.Z., Wu X.L., Yu M.Q., et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117 3 (2003) 190-194
154. Pradier O., Hille A., Schmiberger H., and Hess C.F. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer Radiother 6 1 (2002) 15-21
155. Ebert W., Dienemann H., Fateh-Moghadam A., Scheulen M., Konietzko N., Schleich T., et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 32 3 (1994) 189-199
156. van der Gaast A., Schoenmakers C.H., Kok T.C., Blijenberg B.G., Cornillie F., and Splinter T.A. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 69 3 (1994) 525-528
157. He Q.Y., Chen J., Kung H.F., Yuen A.P., and Chiu J.F. Identification of tumour associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 4 1 (2004) 271-278
158. Chen J., He Q.Y., Yuen A.P., and Chiu J.F. Proteomics of buccal squamous carcinoma: the involvement of multiple pathways in tumoregenesis. Proteomics 4 8 (2004) 2465-2475
159. Baker H., Patel V., Molinolo A.A., Shillitoe E.J., Ensley J.F., and Yoo G.H. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture micro dissection and tandem mass spectrometry. Oral Oncol 41 2 (2005) 183-199
160. Lo W.Y., Tsai M.H., Tsai Y., Hua C.H., Tsai F.J., and Huang S.Y. Identification of overexpressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 376 1-2 (2007) 101-107